{"data":{"id":"us-ne/neb.-rev.-stat.-71-9602","jurisdiction":"us-ne","citation":"Neb. Rev. Stat. § 71-9602","heading":"Terms, defined.","body":"For purposes of the Investigational Drug Use Act:\n(1) Advanced illness means any progressive disease or medical or surgical condition that entails significant functional impairment, that is not considered by a treating physician to be reversible even with administration of federally approved and available treatments, and that, without life-sustaining procedures, would likely result in death within six months;\n(2) Eligible patient means a person who meets the requirements of section 71-9603;\n(3) Health care provider has the same meaning as in section 71-7907;\n(4) Investigational drug, biological product, or device means any drug, biological product, or device that has successfully completed phase one of a clinical trial but has not yet been approved for general use by the United States Food and Drug Administration and remains under investigation in a clinical trial approved by the United States Food and Drug Administration;\n(5) Physician means any person who is licensed to practice medicine and surgery pursuant to the Medicine and Surgery Practice Act; and\n(6) Written, informed consent means a writing which conforms to section 71-9604.","path":["Chapter 71 - PUBLIC HEALTH AND WELFARE"],"source_url":"https://nebraskalegislature.gov/laws/statutes.php?statute=71-9602","current_through":"Laws 2026","vintage":"","retrieved_at":"2026-10-18T06:03:47Z","sha256":"586773afca971553eac405de107703bd2d1d5a8d01a45671b14480b477257b70","source_id":"us-ne","stale":false,"prev":"us-ne/neb.-rev.-stat.-71-9601","next":"us-ne/neb.-rev.-stat.-71-9603"},"notice":"GroundRules: Original legal text. Not legal advice."}